| Friday | ||||
Bullish option flow… Bullish option flow detected in Viatris with 1,955 calls trading, 1.5x expected, and implied vol increasing almost 3 points to 29.20%. Feb-23 12 calls and Jan-24 15 calls are the most active options, with total volume in those strikes near 1,000 contracts. The Put/Call Ratio is 0.16. Earnings are expected on February 27th. | ||||
Jefferies analyst Glen… Jefferies analyst Glen Santangelo upgraded Viatris to Buy from Hold with a price target of $15, up from $13, after management "laid out a clear roadmap and strategic update" in conjunction with Q3 results, closed the Biocon transaction was on November 29 and acquired two ophthalmology companies. The firm's updated estimates better reflect the impact from Biocon, recent M&A, planned non-core asset sales, business development and share repurchases and given the pro forma estimates for 2024, the pro forma valuation "paints a new picture," the analyst tells investors. | ||||
Jefferies analyst Glen… Jefferies analyst Glen Santangelo upgraded Viatris to Buy from Hold with a price target of $15, up from $13. | ||||
| Tuesday | ||||
Bearish flow noted in… Bearish flow noted in Viatris with 2,607 puts trading, or 1.6x expected. Most active are Feb-23 11.5 puts and Jan-24 12 puts, with total volume in those strikes near 1,800 contracts. The Put/Call Ratio is 1.76, while ATM IV is up nearly 3 points on the day. Earnings are expected on February 27th. | ||||
| Over a week ago | ||||
Bullish option flow… Bullish option flow detected in Viatris with 7,126 calls trading, 4x expected, and implied vol increasing over 10 points to 39.72%. Feb-23 12 calls and 3/3 weekly 11.5 puts are the most active options, with total volume in those strikes near 6,100 contracts. The Put/Call Ratio is 0.19. Earnings are expected on February 27th. | ||||
Bullish option flow… Bullish option flow detected in Viatris with 7,965 calls trading, 6x expected, and implied vol increasing almost 5 points to 33.62%. Feb-23 13 calls and Feb-23 12 calls are the most active options, with total volume in those strikes near 6,100 contracts. The Put/Call Ratio is 0.07. Earnings are expected on February 27th. | ||||
Bullish option flow… Bullish option flow detected in Viatris with 1,843 calls trading, 1.4x expected, and implied vol increasing over 5 points to 32.64%. Jan-23 11 calls and Jan-23 10 puts are the most active options, with total volume in those strikes near 1,200 contracts. The Put/Call Ratio is 0.61. Earnings are expected on February 27th. | ||||
| Over a month ago | ||||
Bearish flow noted in… Bearish flow noted in Viatris with 2,061 puts trading, or 1.4x expected. Most active are 12/30 weekly 11 calls and 1/6 weekly 11 puts, with total volume in those strikes near 1,600 contracts. The Put/Call Ratio is 1.51, while ATM IV is up nearly 18 points on the day. Earnings are expected on February 27th. | ||||
Viatris announced that… Viatris announced that its near-term science-based emissions reduction targets have been approved by the Science Based Targets initiative. SBTi is a global body enabling businesses to set ambitious emissions reduction targets in line with the latest climate science. Viatris announced its initial companywide sustainability goals, including environmental targets, earlier this year. The SBTi classified Viatris' scope 1 and 2 target ambition and has determined that it is in line with a 1.5 degrees C trajectory, a worldwide goal of limiting global warming. The company's climate targets are: Viatris commits to reduce absolute scope 1 and 2 GHG emissions 42% by 2030 from a 2020 base year. Viatris Inc. also commits to reduce absolute scope 3 GHG emissions covering purchased goods and services, capital goods, fuel and energy related activities, and upstream transportation and distribution 25% within the same timeframe. | ||||
Calliditas Therapeutics… Calliditas Therapeutics (CALT) announced that they have entered into an exclusive license agreement with Viatris (VTRS), to register and commercialize Nefecon, a specialty drug recently approved in Europe and the U.S. for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy, or IgAN, in Japan. Under the terms of the agreement, Calliditas is entitled receive an initial upfront payment of $20M upon signing and up to an additional $80M in pre-defined development and commercialization milestones. Viatris will also pay mid-teens percentage royalties on net sales. IgAN, also known as Berger's disease, is a rare and serious progressive autoimmune disease in which up to 50% of patients end up at risk of developing end stage renal disease and thus requiring dialysis or a kidney transplant. | ||||
